Clinical Trials Logo

Filter by:
NCT ID: NCT01830972 Completed - GNE Myopathy Clinical Trials

An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy

Start date: June 4, 2013
Phase: Phase 2
Study type: Interventional

The safety objectives of the study are to: evaluate additional long-term safety of SA-ER treatment of participants with GNE myopathy previously treated with SA-ER at dose of 6g/day (Part I); evaluate the safety of 12g /day SA (delivered by 1.5g of SA-ER tablets and 1.5g of SA-IR capsules 4 times per day) in the treatment of participants with GNE myopathy (Part II) over a 6 month treatment period; evaluate the safety of SA treatment at both 6g/day and 12 g/day (Part III [SA-ER/SA-IR] and Part IV [SA-ER]).

NCT ID: NCT01830894 Not yet recruiting - Clinical trials for Intra Cerebral Hemorrhage

Feasibility Study of New MRI Protocol in Assessing Early Blood Brain Barrier Disruption (BBBD)in Related to Delay Brain Edema

BBBD
Start date: April 2013
Phase: Phase 1/Phase 2
Study type: Interventional

MRI research Group in the Advanced Technology Center of the Sheba Medical Center has developed an innovative methodology based on leakage (extravasation) contrast agent that allows to map the entire brain with high resolution and high sensitivity to check and describe disorders BBB (blood brain barrier). The aim of the current study is to evaluate the feasibility of the BBB disruption detection method to predict delayed peri - hemorrhage edema.

NCT ID: NCT01829711 Completed - Clinical trials for Leukemia, Hairy Cell

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Start date: April 29, 2013
Phase: Phase 3
Study type: Interventional

Background: - Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase III multicenter trial designed to confirm these results.

NCT ID: NCT01828853 Not yet recruiting - Sepsis Clinical Trials

Maternal and Neonatal Outcomes After Membrane Sweeping

Stripping
Start date: April 2013
Phase: N/A
Study type: Observational [Patient Registry]

This study aim to estimate maternal and neonatal outcomes after membrane sweeping in different group of patients.

NCT ID: NCT01828840 Completed - Clinical trials for Post Laparotomy Pain Treatment

A Prospective Comparison of Methadone, Fentanyl, and Morphine for Post-laparotomy Epidural Analgesia

Start date: April 2014
Phase: N/A
Study type: Interventional

The current study aim is to compare between the opioids morphine, fentanyl and methadone in terms of efficacy and side effects profile when administered epidurally for pain management after laparotomies. Intravenous morphine will also be used. The outcomes of that method will be compared to those obtained using epidurally administered opioids, as this is another commonly used postoperative pain relief method.

NCT ID: NCT01828580 Completed - Clinical trials for Patients Scheduled for Hernia Repair, Cholecystectomy, Right Colectomy, Nissen Fundoplication and Sigmoid Resection

Safety and Performance Evaluation of the AutoLap System

Start date: December 2012
Phase: N/A
Study type: Interventional

The main objectives of this study are to evaluate the safety and performance of the AutoLap system in Laparoscopic Cholecystectomy procedures.

NCT ID: NCT01828528 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease

Start date: April 2013
Phase: N/A
Study type: Observational

The purpose of this study is to investigate the effect of weight loss rate on liver steatosis, steatohepatitis, fibrosis and cardiovascular risk at different stages before and after bariatric surgery. The investigators also aim to study the short-term effect of bariatric surgery on gastric cholecystokinin levels before and 10 days after the bariatric surgery.

NCT ID: NCT01828190 Completed - Crohn's Disease Clinical Trials

The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers

Start date: March 2013
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the effect of hyperbaric oxygen therapy (HBOT) on patient suffering from residual Crohn's disease related perianal fistulas already treated with TNF alpha blockers

NCT ID: NCT01828112 Completed - Clinical trials for Non-Small Cell Lung Cancer

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Start date: June 28, 2013
Phase: Phase 3
Study type: Interventional

The primary purpose of the study was to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib. Patients in the chemotherapy arm were given the option to switch to LDK378 after confirmed progressive disease (PD), while also had the choice to continue with pemetrexed treatment.

NCT ID: NCT01827683 Completed - Fibromyalgia Clinical Trials

Hyperbaric Oxygen and Fibromyalgia: Randomised Prospective Clinical Trial

Start date: May 2010
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the effect of hyperbaric oxygen therapy (HBOT) on patients suffering from chronic pain syndrome (Fibromyalgia).